Anton Clarke Atwell

Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France.

The Schepens Eye Research Institute, Inc. operates as an eye research institute. It offers treatment for macular degeneration, diabetic retinopathy, glaucoma, other types of retinal and optic nerve degenerations and damage, dry eye and eye tissue transplants. The company was founded by Charles L. Schepens in 1950 and is headquartered in Boston, MA.

Massachusetts Eye & Ear Infirmary operates as hospital that provides patient care for disorders of the eye, ear, nose, throat, head and neck. It offers ophthalmology and otolaryngology research services and is a teaching partner of Harvard Medical School. The firm’s programs and services include anesthesiology, ophthalmology, otolaryngology, radiology, Coolidge Clinic laboratory and libraries. The company was founded in 1824 and is headquartered in Boston, MA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

GelMEDIX, Inc. operates as a biotechnology technology. The company is headquartered in Newton, MA.

Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company based in Medfield, MA. Aramis Biosciences is committed to developing disease-modifying therapy for ocular surface disease, starting with dry eye disease. The company's lead product candidate, A197, is a novel, first-in-class, topical immunomodulatory agent currently in a phase II clinical proof of concept for the treatment of dry eye disease. The company was founded in 2018 by Sunil Chauhan, Reza Dana, and the CEO is David S. Tierney. Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation, and immunology from the Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, with support from Safar Partners, Dompé Farmaceutici S.p.A., and a leader in ophthalmic pharmaceuticals.

Safar Partners LLC (Safar Partners) is a venture capital firm founded in 2019 by Nader Motamedy. The firm is headquartered in Cambridge, Massachusetts.

Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel.

Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California.

Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden.

Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA.

Aristea Therapeutics, Inc. operates as a clinical-stage drug development company. It develops novel therapies to treat serious inflammatory diseases. The company was founded by James Morrison MacKay in 2018 and is headquartered in Poway, CA.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Part of University of California, California Institute For Quantitative Biosciences is a biotech company that offers internships to UC students through its state-funded Qwest internship program. The company is based in San Francisco, CA and was founded in 2000. The program places students with Bakar Labs tenant companies for work experience, and four of its first cohort have already received full-time job offers from their hosts. The company conducts proof-of-concept experiments in a mouse model of ALS and offers mentoring programs to early-stage companies.

Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023.

The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium.

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium.

Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.